Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis

Detaylı Bibliyografya
Asıl Yazarlar:	Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2013

Benzer Materyaller

LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Yazar:: Baraliakos, X, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Yazar:: Van Laar, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS
Yazar:: Emery, P, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.
Yazar:: Baraliakos, X, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging
Yazar:: Baraliakos, X, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Yazar:: Baeten, D, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Yazar:: Baeten, D, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
Yazar:: J. Braun, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
Yazar:: Lubrano E, ve diğerleri
Baskı/Yayın Bilgisi: (2016-10-01)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Yazar:: A. Deodhar, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Role of secukinumab in ankylosing spondylitis with tubercular uveitis
Yazar:: Padmamalini Mahendradas, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
Yazar:: Purmonen T, ve diğerleri
Baskı/Yayın Bilgisi: (2019-02-01)

Effectiveness of secukinumab for overlapping hidradenitis suppurativa and ankylosing spondylitis
Yazar:: Mariam AlAfeefi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
Yazar:: van der Heijde, D, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis
Yazar:: Taylor, P, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
Yazar:: Elena Conesa-Nicolás, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study
Yazar:: Uta Kiltz, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
Yazar:: Atul A. Deodhar, ve diğerleri
Baskı/Yayın Bilgisi: (2020-05-01)

The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis
Yazar:: Ahmet Karataş, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
Yazar:: Ashley Elliott, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

THE UNCHANGEABLE ESSENCE BUT CHANGEABLE AND UNCHANGEABLE ATTRIBUTES
Yazar:: Ahmad Beheshti
Baskı/Yayın Bilgisi: (2012-07-01)

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
Yazar:: van der Heijde, D, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
Yazar:: Xenofon Baraliakos, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
Yazar:: S. K. Zyryanov, ve diğerleri
Baskı/Yayın Bilgisi: (2017-04-01)

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
Yazar:: Tahir H, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Ankylosing spondylitis: evidence for a non-HLA-B*27 protective effect.
Yazar:: van der Linden, S, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial
Yazar:: van der Heijde, D, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.
Yazar:: Van der Heijde, D, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature
Yazar:: Alexander Zheutlin, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
Yazar:: Dean Ehrlich, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis
Yazar:: Sumera Ghani, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
Yazar:: Jürgen Braun, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
Yazar:: Casper Webers, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Yazar:: Alice B. Gottlieb, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

THE GENETICS OF ERAP1 IN ANKYLOSING SPONDYLITIS
Yazar:: Wordsworth, B, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) patients: Results from ATLAS.
Yazar:: van der Heijde, D, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Genetics of ankylosing spondylitis.
Yazar:: Brown, M, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Health promotion and the ‘unchanging need’ to change
Yazar:: R. P. P. Karunapema, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs
Yazar:: Yu Zhou, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)